Cost Review Study Process Updates

​Written Comment Request: Posted 10/28/2024
In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:  
Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged.  Written comments are due by the close of business, Friday, November 8, 2024. Please submit written comments to comments.pdab@maryland.gov​ with the subject line “(Drug Name) Comments.”


ARCHIVE:

Drugs Referred to Stakeholder Council

The comment period for Drugs Referred to the Stakeholder Council begins April 10, 2024. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Drugs Referred to the Stakeholder Council Comment" in the subject line.

Drugs Referred to the Stakeholder Council

Comments Received for Drugs Referred to Stakeholder Council

Therapeutic Alternatives

The comment period for Therapeutic Alternatives (for Drugs Referred to the Stakeholder Council) begins April 10, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives" in the subject line.

The comment period for Therapeutic Alternatives for Drugs Referred to the Stakeholder Council begins April 11, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Monday, May 13, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives" in the subject line.

Comments Received for Therapeutic Alternatives

Additional Information